Bharat Biotech develops first vaccine candidate for Zika virus
Indian pharmaceuticals company Bharat Biotech is developing the first vaccine candidates for the Zika virus. The company has two candidates in development for their Zikavac vaccine: a recombinant vaccine and an inactivated vaccine that has reached pre-clinical animal testing.
The company’s interest in Zika virus, an obscure virus when we started the project a year ago was that the clinical features at an early stage of infection are indistinguishable from that of Dengue and Chikungunya.
“Considering that women of childbearing age and pregnant women are the prime target group for Zika virus vaccine, we consider safety as the overriding factor in development of a new vaccine for this virus. The vaccine methods developed early on, before the devastating consequences of the epidemics in Brazil came to light provided us a push to accelerate vaccine development,” Dr. Sumathy, Director R&D Bharat Biotech said.
“The first thing is to be prepared for the worst,” says says Dr. Krishna Ella said who along with Dr. Sumathy and the R&D team at Bharat Biotech is working in the Zika vaccine program said. We hope to announce its arrival of Zikavac to the world as early as possible.
Category: Features, Pharmaceuticals
Subscribe
If you enjoyed this article, subscribe to receive more just like it.
